Navigation Links
Simbionix Announces Initiation of the REHEARSAAAL Study
Date:10/24/2013

CLEVELAND, October 24, 2013 /PRNewswire/ --

Simbionix, a leading provider of innovative training solutions, announced the initiation of the REHEARSAAAL study which evaluates the clinical benefits of preoperative patient specific simulation using the PROcedure Rehearsal Studio™ for the treatment of Abdominal Aortic Aneurysms (AAAs) by Endovascular Aortic Repair (EVAR). This study will be conducted by multidisciplinary group of physicians from vascular surgery, interventional radiology and cardiology departments in hospitals across the United States and Europe.

     (Logo: http://photos.prnewswire.com/prnh/20120502/529202-a)

PROcedure Rehearsal Studio allows physicians to create a 3D anatomical model based on a patient's individualized CT scan to simulate, analyze and evaluate preoperative surgical options. The availability of patient specific technology allows the interventional team to engage in simulated practice procedures utilizing a patient's own anatomy prior to performing an actual procedure, potentially leading to more precise treatment decisions, a reduction of errors, improved outcomes, and enhanced operator confidence.  Prior case simulation may allow patients to have a shortened procedure with less time under sedation, a reduction in radiation exposure, and a decrease in procedural complications.

This two-arm study will randomize 150 patients in 1:1 ratio, stratified by operator's experience and procedure complexity. It compares real EVAR procedure parameters with an emphasis on radiation exposure time and safety parameters. Physicians treating patients enrolled for the preoperative patient specific simulation group will go through the simulated experience - a virtual practice session - prior to performing the real case.  Outcomes in these patients will be compared to procedures performed without prior simulated practice as is routinely done.

Dr. John Rundback, Medical Director, Interventional Institute at Holy Name Medical Center and the study's Principal Investigator, "Simulation has proven experience in the aviation and other industries in improving performance and reducing errors. The Simbionix PROcedure Rehearsal Studio provides a platform to practice and optimize procedures using personalized patient data in advance of performing live cases, assuring an unparalleled opportunity to streamline all aspects of the actual procedure, improve patient safety, and reduce the use of additional costly devices that are often needed when procedures are unable to be rehearsed."

See the PROcedure Rehearsal Studio at TCT in booth # 2408 and at VEITH in booth # 110.

About Simbionix:

Simbionix is committed to delivering quality products, advancing clinical performance and optimizing procedural outcomes. http://www.simbionix.com

Rebecca Levy, Marketing Communications Manager, rebecca@simbionix.com; +1-216-229-2070#128


'/>"/>
SOURCE Simbionix Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Após o sucesso do lançamento nos Estados Unidos, o novo U/S Mentor da Simbionix será introduzido pela primeira vez na Europa
2. Inflamax Research, Inc. Announces Fully-Integrated Clinical e-Source Data Management Services
3. The Comfort Outlet Announces No Shipping Costs on All Outlast Mattress Pads
4. Brainwave Signal Interpretation Software Company EyeMynd Announces Move to Silicon Valley
5. The Conference Forum Announces the Launch of the 2nd Annual Medicaid Rebate Summit
6. Genufood Energy Enzymes Corp. Announces $20 Million Equity Purchase Agreement
7. Elan Wellness Center Announces Theralase Therapeutic Laser Treatment is Now Available
8. Jeeven BioSciences, Inc. Announces the Release of Its Neuro-XTM Serum-Free and Xeno-Free Tissue Culture Media
9. Spartan Bioscience Announces Medical Device Registration of Rapid CYP2C19 Testing System in Saudi Arabia
10. TM&S, LLC Announces Representation of ecoMIM
11. QIAGEN Announces Partnership With Clovis Oncology to Co-develop Companion Diagnostic Targeting Drug-Resistant EGFR Mutations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... Connecticut (PRWEB) , ... May 25, 2016 , ... ... the U.S. Food and Drug Administration (FDA) has granted the company’s orphan drug ... the company’s second orphan drug designation granted by the FDA. , Spinocerebellar ...
(Date:5/23/2016)... ... ... blood donations in South Texas and across the nation is growing. , But according to ... are on the decline. In fact, donations across the country are at their lowest point ... the last four years alone. , There is no substitute for blood. , “We want ...
(Date:5/23/2016)... ... May 23, 2016 , ... RoviSys, a ... based in Aurora, Ohio, has broken ground on a new building in Holly ... Park area, this new location solidifies a commitment to business in the region. ...
(Date:5/20/2016)... ... 2016 , ... Korean researchers say Manumycin A triggers apoptosis, or natural cell ... treat the disease. Surviving Mesothelioma has just posted an article on the new study. ... based their mesothelioma study on the fact the Manumycin A, a derivative of Streptomyces ...
Breaking Biology Technology:
(Date:3/14/2016)... , March 14, 2016 NXTD ... growing mobile commerce market, announces the airing of a new ... starting the week of March 21 st .  The commercials ... including its popular Squawk on the Street show. --> ... on the growing mobile commerce market, announces the airing of ...
(Date:3/11/2016)... -- --> --> ... Market by Technology (Pattern Recognition), by Component (Hardware, Software, ... (On-Premises and Cloud), by Industry Vertical and by Region ... global market is expected to grow from USD 12.49 ... at a CAGR of 19.1%. , ...
(Date:3/9/2016)... This BCC Research report provides an overview ... Sequencing (RNA Seq) market for the years 2015, 2016 ... reagents, data analysis, and services. Use this ... market such as RNA-Sequencing tools and reagents, RNA-Sequencing data ... each segment and forecast their market growth, future trends ...
Breaking Biology News(10 mins):